Latest Press Releases View all Jun 01, 2026 Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy May 11, 2026 Vertex to Participate in Upcoming May Investor Conferences May 06, 2026 Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany View all Featured Media Library Items View all Reshma Kewalramani, M.D. Chief Executive Officer and President Download Duncan McKechnie Executive Vice President and Chief Commercial Officer Download Vertex International Headquarters – Lobby Download View all
Jun 01, 2026 Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
May 06, 2026 Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany